Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

OBJECTIVE: Among patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin combination produced greater reductions in glycemia, weight, and systolic blood pressure (SBP) at 28 weeks than exenatide QW or dapagliflozin alone (DURATION-8). Here, we investi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Care
Main Authors: Jabbour, Serge A., Frías, Juan P., Hardy, Elise, Ahmed, Azazuddin, Wang, Hui, Öhman, Peter, Guja, Cristian
Formato: Artigo
Idioma:Inglês
Publicado em: American Diabetes Association 2018
Assuntos:
Emerging Therapies: Drugs and Regimens
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6150435/
https://ncbi.nlm.nih.gov/pubmed/30082326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc18-0680
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados